Overview

Editors:

• Lucyna Antkiewicz-Michaluk⁰,
• Hans Rommelspacher¹

1. Lucyna Antkiewicz-Michaluk

   1. Krakow, Poland
      

   View editor publications

   You can also search for this editor inPubMed Google Scholar

2. Hans Rommelspacher

   1. , Departments of Psychiatry, Charité-University Medicine, Berlin, Germany
      

   View editor publications

   You can also search for this editor inPubMed Google Scholar

       The specific topic, “Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants – New Perspectives In Parkinson`S Disease Therapy,” was chosen in light of accumulating neurobiological evidence indicating that, in addition to exogenous neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP]), endogenous compounds may play an important role in the most common neurodegenerative disorders (e.g., Parkinson`s disease). Two groups of amine related compounds, which appeared chemically like MPTP, were detected in human brain and cerebrospinal fluid (CSF):ß-carbolines (BCs) and tetrahydroisoquinolines  (TIQs). These are heterocyclic compounds formed endogenously from phenylalanine/tyrosine (TIQs) and tryptophan, tryptamine, and 5-hydroxytryptamine (BCs), respectively and exert a wide spectrum of psychopharmacological and behavioral effects. The TIQs and BCs may bind to their own high affinity sites on neuronal membranes associated with or located close to the receptors of neurotransmitters. Research on TIQs and BCs is stimulated also by their possible role in pathological conditions, especially parkinsonism and alcoholism. Recently, clinical interest has been spurred by their role as neuroprotective, and even neurorestorative, anticonvulsant and antiaddictive, substances.

In this book we are going to summarize, for the first time, the results from behavioral, neurochemical and molecular experiments, which demonstrate a wide spectrum of TIQs and BCs effects - from their rather mild neurotoxic actions to the important neuroprotective and antiaddictive properties.

Additionally, the recent results of experimental studiesin vivo have allowed a much better understanding and simultaneous comparison of the neurochemical and molecular mechanisms underlying the neuroprotective and neurotoxic actions of endogenous TIQs and BCs and have pointed to the possibility oftheir therapeutic applications in neurodegenerative diseases such as Parkinson's disease.

• Krakow, Poland

  Lucyna Antkiewicz-Michaluk

• , Departments of Psychiatry, Charité-University Medicine, Berlin, Germany

  Hans Rommelspacher

Policies and ethics